On the stock market since 2021, it operates in the world of health and science. It has 10 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 23 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $52.4M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
The stock trades 92% above the average analyst price target.
On our five-subject report card, IKNA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IKNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.